Track topics on Twitter Track topics that are important to you
Neurodegeneration company AC Immune S.A. (NASDAQ:ACIU) raised $66 million through the sale of 6 million shares at $11 in an IPO underwritten by Credit Suisse, Jefferies and Leerink. The price valued the company at $609.4 million. AC Immune expects its shares to begin trading on Friday.
On Wednesday, AC Immune said it hoped to sell 6 million shares at $11-$13. Last week, it proposed to sell 4.5 million shares at the same price range.
AC Immune's lead program is crenezumab (RG7412), a humanized mAb against beta amyloid to treat prodromal to mild Alzheimer's disease. Its partner, the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), began a Phase III study of the candidate in 1Q16.
Original Article: AC Immune prices $66M IPONEXT ARTICLE
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase 'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...
Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...